Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

recautions (5.2), and Adverse Reactions (6.1, 6.3)].

The most common adverse events of Vectibix are skin rash with variable presentations, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea, and diarrhea, including diarrhea resulting in dehydration.

Important European Product Safety Information

For full prescribing information please see the Summary of Product Characteristics.

Vectibix is indicated as monotherapy for the treatment of patients with EGFR-expressing, mCRC with nonmutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Vectibix is contraindicated in patients with a history of severe or life-threatening hypersensitivity reactions to the product and in patients with interstitial pneumonitis or pulmonary fibrosis.

Other common adverse events of special importance associated with Vectibix and/or EGFR monoclonal antibody therapies include dermatologic-related reactions, pulmonary complications, electrolyte disturbances and infusion-related reactions (including rare reports with fatal outcome). These events should be monitored carefully, see Summary of Product Characteristics for information on appropriate management of these adverse events. Acute renal failure has been observed in patients who develop severe diarrhoea and dehydration.

Vectibix should not be used in combination with IFL [bolus 5-fluorouracil (500 mg/m2), leucovorin (20 mg/m2) and irinotecan (125 mg/m2)] or in combination with bevacizumab containing chemotherapy.

Vectibix should not be administered in combination with oxaliplatin-containing chemotherapy to mCRC patients with mutant KRAS tumors or for whom KRAS tumor status is unknown.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first compan
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... BioClinica®, Inc., a leading provider of outsourced ... of its experts are speaking at the 20th ... be held September 28 to October 1 in ... announced the innovative Compass technology, a risk-based ... acquired earlier this year, is up for the ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced ... of the cost and predictability of non-adherence in type ... Meeting of the European Association for the Study of ... Frois , Ph.D., of Analysis Group, Inc. presented data ... retrospective studies to characterize the prevalence of non-adherence and ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... FOREST, California , 17 de septiembre ... CYRX) ("la compañía"), principal proveedor mundial de ... de las ciencias de la vida, anunció ... compañía de logística global con sede en ... su base de clientes Europa en rápido ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... Calif., June 6 InterMune, Inc.,(Nasdaq: ITMN ) ... Financial Officer of InterMune, will present at the Goldman ... on,June 10, 2008 at 8:05 a.m. PDT (11:05 a.m. ... Needham & Company, LLC Biotechnology and,Medical Technology Conference in ...
... 5 BioTrends Research Group, Inc.,released its third ... management of psoriasis. This report is based on,responses ... Dermatologists in April,2008., According to the study, ... use of biologics for the treatment of psoriasis ...
... BioTrends Research Group, Inc. is,pleased to announce the ... is based on the results of an on-line ... France, Germany, Italy, and Spain.,The report focuses on ... In the ESA market, Amgen,s Aranesp is ...
Cached Biology Technology:InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis 2New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists 2
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... the Columbia Center for Children,s Environmental Health at the ... demonstrate an association between childhood asthma and prenatal exposure ... household products. Results appear online in the journal ... mothers exposed during pregnancy to higher levels of the ... a 72 percent and 78 percent increase in risk ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... the results of the Oats at 10 Years study, marking ... claim that oats, as part of an overall heart healthy ... written by Mark B. Andon, PhD, and James W. Anderson, ... claim, theorizing that foods containing whole-oat sources of soluble fiber ...
... University bioengineer Jennifer West is being recognized today with ... the O,Donnell Award from The Academy of Medicine, Engineering ... given for excellence in medical, scientific and engineering research, ... statue. West, a pioneer in the field of biomaterials ...
... of Alberta for those who may have overindulged during the recent ... a way to reduce the amount of bad cholesterol and fatty ... metabolizes, a key discovery that could lead to new drugs to ... disease related to obesity. In a series of recently ...
Cached Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels 2
... The Sub-Plates are E.Coli glycerol stocks contained ... contains 50 cDNA clones with approximately 5,000 ... the a master plate well, the corresponding ... PCR to identify the positive well(s). Cells ...
... 0.9 ml per liter of urine will give ... or BMD dipstick. ,Certification: The Donors are ... found to be NEGATIVE for HbsAg, HCV, HIV-1 ... approved FDA methods. THIS MATERIAL IS SOLD FOR ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... light production by luciferase-cDNA transfected cell lines ... in the development of reporter gene assays ... an indicator for the transcription of other ... is due to advantages such as high ...
Biology Products: